Population Pharmacokinetics and Pharmacodynamics of Disulfiram on Inducing Latent HIV-1 Transcription in a Phase IIb Trial
Sulggi A Lee, Julian H Elliott, James McMahon, Wendy Hartogenesis, Namandje N Bumpus, Jeffrey D Lifson, Robert J Gorelick, Peter Bacchetti, Steven G Deeks, Sharon R Lewin, Radojka M Savic
Clinical Pharmacology & Therapeutics | WILEY | Published : 2019
Awarded by National Institutes of Health (DARE Collaboratory)
Awarded by Foundation for AIDS Research
Awarded by National Cancer Institute, National Institutes of Health
This work was supported in part by the National Institutes of Health (the DARE Collaboratory (U19 AI096109), S.A.L.: K23GM112526, R.M.S.: KL2TR000143) the Foundation for AIDS Research (S.G.D.: 108072--50-RGRL), and the Australian National Health and Medical Research Council (S.R.L.: Australian National Health and Medical Research Council (NHMRC) Practitioner Fellowship; J.H.E.: NHMRC Career Development Fellowship). This work was also supported in part with federal funds from the National Cancer Institute, National Institutes of Health, under Contract No. HHSN261200800001E. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.